Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Follow-Up Questions
Who is the CEO of Allarity Therapeutics Inc?
Mr. Thomas Jensen is the Chief Executive Officer of Allarity Therapeutics Inc, joining the firm since 2020.
What is the price performance of ALLR stock?
The current price of ALLR is $1.5, it has increased 4.23% in the last trading day.
What are the primary business themes or industries for Allarity Therapeutics Inc?
Allarity Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Allarity Therapeutics Inc market cap?
Allarity Therapeutics Inc's current market cap is $21.9M
Is Allarity Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Allarity Therapeutics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
